Tuesday, May 7, 2024
Home Internet News Accelerator Page 3

Accelerator

    Most popular

    Initiating Coverage on Mitesco (MITI) FKA True Nature Holdings (TNTY) $0.02. Adding to Watch...

    Internet News Editor / Curator -
    Click here to download.
    True Nature, Mitesco, Biotech Stock Review

    Is True Nature (TNTY) $0.04, Nearing a Breakout?

    Incubator Editor / Curator -
    After a Tough Year, a Series of Development Releases Appears to Have Halted True Natures Downtrend and Move to a Possible...
    True Nature, Mitesco, Biotech Stock Review

    True Nature’s (TNTY) CEO Larry Diamond on Wall Street Analyzer.

    Accelerator Editor / Curator -
    Larry Diamond Reveals Some of True Nature's Goals and Ambitions to Incubate Medical Related Startups to Benefit All Shareholders.
    True Nature, Biotech Stock Review

    True Nature | Mitesco (TNTY), Perking Up.

    Accelerator Editor / Curator -
    Is it too early to nick-name True Nature's Medtech incubator Mitesco the "Mighty Mitesco?" Of course it's too early - but it...

    Stand Down IV: Remember This? Alta Vista Cancels IPO. David Wetherell Takes a $2...

    Stand Down. Editor / Curator -
    We are going through some of our very old 'incubator files' back from when we ran the Incubator Stock Review, a spinoff...
    123Page 3 of 3

    Latest article

    We’re in Tampa for the Kentucky Derby.

    2024 Watch List Editor / Curator -
    GeoVax (GOVX), Sees a Little Volume. Normally, we get a little nervous when one of the companies we...

    Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.

    Institutional Analyst Newsletter Editor / Curator -
    DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.